Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Disc Medicine, Inc. - Common Stock (NQ: IRON ) 65.00 +1.67 (+2.64%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Disc Medicine, Inc. - Common Stock < Previous 1 2 3 4 Next > Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA) March 21, 2023 IND accepted for phase 2 clinical trial in DBA patients; study is expected to initiate mid-year 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Opco Inc (NASDAQ: IRON) Investor Notice: Investigation over Possible Securities Laws Violations March 20, 2023 San Diego, CA -- (SBWIRE) -- 03/20/2023 -- An investigation was announced for investors of Disc Medicine Opco Inc (NASDAQ: IRON) shares over potential securities laws violations in connection with... Via SBWire Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement March 18, 2023 Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had... Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 February 28, 2023 Via Benzinga $2M Bet On PayPal? Check Out These 4 Stocks Insiders Are Buying February 21, 2023 Although US stocks closed mixed on Friday, there were a few notable insider trades. Via Benzinga Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia February 16, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs February 14, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine to Participate in SVB Securities Global Biopharma Conference February 08, 2023 From Disc Medicine Inc Via GlobeNewswire Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million January 21, 2023 Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in... Via Talk Markets Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis January 20, 2023 From Disc Medicine Inc Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 January 04, 2023 Via Benzinga Stocks Stumbling Out Of 2023's Gate January 03, 2023 Stocks were unable to fulfill premarket gains, as two familiar foes -- rising rates and high inflation -- dampen investor sentiment to start the new trading year. Via Talk Markets 12 Health Care Stocks Moving In Tuesday's Pre-Market Session January 03, 2023 Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
